| scholarly article | Q13442814 |
| P2093 | author name string | Michael N Pollak | |
| Laurent Azoulay | |||
| Samy Suissa | |||
| Hui Yin | |||
| Brielan B Smiechowski | |||
| P2860 | cites work | Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. | Q54631030 |
| Prostate cancer risk among men with diabetes mellitus (Spain) | Q81262002 | ||
| Epidemiology of Lung Cancer | Q22306069 | ||
| Metformin in cancer: translational challenges | Q26866388 | ||
| Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs | Q28174919 | ||
| Validity of diagnostic coding within the General Practice Research Database: a systematic review | Q33689383 | ||
| Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. | Q33718914 | ||
| Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. | Q34086275 | ||
| Metformin and other biguanides in oncology: advancing the research agenda | Q34196114 | ||
| Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission | Q34611836 | ||
| Cohort study of pioglitazone and cancer incidence in patients with diabetes | Q34718437 | ||
| Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis | Q35333423 | ||
| Use of the UK General Practice Research Database for pharmacoepidemiology | Q35802395 | ||
| Immortal time bias in pharmaco-epidemiology | Q37023172 | ||
| Metformin beyond diabetes: new life for an old drug | Q37065677 | ||
| New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes | Q37319178 | ||
| Insulin, insulin resistance, obesity, and cancer | Q37738720 | ||
| Metformin and cancer: new applications for an old drug | Q37837675 | ||
| The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. | Q40021818 | ||
| Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth | Q40105523 | ||
| Diabetes and the risk of lung cancer | Q43948632 | ||
| Immortal time bias in observational studies of drug effects | Q44123059 | ||
| Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan | Q44665632 | ||
| Validity of the General Practice Research Database | Q47921352 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| lung cancer | Q47912 | ||
| patient | Q181600 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 124-129 | |
| P577 | publication date | 2012-08-24 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | The use of metformin and the incidence of lung cancer in patients with type 2 diabetes | |
| P478 | volume | 36 |
| Q33607800 | Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis |
| Q35200421 | Association of the metformin with the risk of lung cancer: a meta-analysis |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q36024628 | Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator |
| Q28386632 | Chemoprevention of lung cancer: prospects and disappointments in human clinical trials |
| Q43242157 | Comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129. |
| Q33748862 | Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis |
| Q36794283 | Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative |
| Q38687543 | Does Metformin Reduce Cancer Risks? Methodologic Considerations |
| Q33650319 | Does chronic obstructive pulmonary disease with or without type 2 diabetes mellitus influence the risk of lung cancer? Result from a population-based cohort study |
| Q37737183 | Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature |
| Q35803926 | Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis |
| Q38098148 | Histamine-2 receptor antagonists and risk of lung cancer in diabetic patients – an exploratory analysis. |
| Q26995495 | Lung cancer chemoprevention: current status and future prospects |
| Q37742183 | Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients |
| Q64226496 | Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis |
| Q38999875 | Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation |
| Q34135248 | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders |
| Q34786488 | Metformin and erlotinib synergize to inhibit basal breast cancer |
| Q41303279 | Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis |
| Q26999266 | Metformin and the risk of cancer: time-related biases in observational studies |
| Q38128357 | Metformin in lung cancer: rationale for a combination therapy |
| Q35046673 | Metformin use and lung cancer risk in patients with diabetes. |
| Q36741232 | Metformin use and young age lung cancer: A case series report |
| Q38393435 | Metformin, an old drug, brings a new era to cancer therapy |
| Q40778391 | No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. |
| Q44440589 | One author replies |
| Q43834371 | Re.: "Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis". |
| Q51771567 | Re: "reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis". |
| Q27025309 | Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis |
| Q43242195 | Response to comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129. |
| Q93148944 | Role of p53 Family Proteins in Metformin Anti-Cancer Activities |
| Q35153493 | Survival of patients with stage IV lung cancer with diabetes treated with metformin |
| Q99365521 | The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer |
Search more.